Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Beaglehole

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
The Australian and New Zealand Journal of Psychiatry|February 9, 2018
Clinical response to treatment in inpatients with depression correlates with changes in activity levels and psychomotor speedIan Re Averill, Marie Crowe, Chris M Frampton, et al.
Journal of Psychopharmacology (Oxford, England)|June 5, 2025
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorderBen Beaglehole, Paul Glue, Shona Neehoff, et al.
Bjpsych Open|October 1, 2025
Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover studyBen Beaglehole, Paul Glue, Shona Neehoff, et al.
The International Journal of Neuropsychopharmacology|July 6, 2026
Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorderShabah M Shadli, Neda Nasrollahi, Calvin K Young, et al.
International Journal of Environmental Research and Public Health|June 10, 2023
The COVID Psychosocial Impacts Scale: A Reliable and Valid Tool to Examine the Psychosocial Impacts of the COVID-19 PandemicSandila Tanveer, Philip J Schluter, Ben Beaglehole, et al.
BMJ Open|May 1, 2024
Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the communityBen Beaglehole, Richard Porter, Katie Douglas, et al.
BMC Psychiatry|February 3, 2019
Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usualIan R E Averill, Ben Beaglehole, Katie M Douglas, et al.
Bipolar Disorders|July 31, 2024
Cognitive predictors of response to interpersonal and social rhythm therapy in mood disordersSamantha J Groves, Katie M Douglas, Marie T Crowe, et al.
Plos One|August 25, 2022
AcceSS and Equity in Transplantation (ASSET) New Zealand: Protocol for population-wide data linkage platform to investigate equity in access to kidney failure health services in New ZealandRachel B Cutting, Angela C Webster, Nicholas B Cross, et al.
Internal Medicine Journal|September 17, 2022
Symptom persistence and recovery among COVID-19 survivors during a limited outbreak in Canterbury, New Zealand: a prospective cohort studyJeanette Cheung, Kim Nordmeier, Sarah Kelland, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
The Australian and New Zealand Journal of Psychiatry|February 9, 2018
Clinical response to treatment in inpatients with depression correlates with changes in activity levels and psychomotor speedIan Re Averill, Marie Crowe, Chris M Frampton, et al.
Journal of Psychopharmacology (Oxford, England)|June 5, 2025
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorderBen Beaglehole, Paul Glue, Shona Neehoff, et al.
Bjpsych Open|October 1, 2025
Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover studyBen Beaglehole, Paul Glue, Shona Neehoff, et al.
The International Journal of Neuropsychopharmacology|July 6, 2026
Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorderShabah M Shadli, Neda Nasrollahi, Calvin K Young, et al.
International Journal of Environmental Research and Public Health|June 10, 2023
The COVID Psychosocial Impacts Scale: A Reliable and Valid Tool to Examine the Psychosocial Impacts of the COVID-19 PandemicSandila Tanveer, Philip J Schluter, Ben Beaglehole, et al.
BMJ Open|May 1, 2024
Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the communityBen Beaglehole, Richard Porter, Katie Douglas, et al.
BMC Psychiatry|February 3, 2019
Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usualIan R E Averill, Ben Beaglehole, Katie M Douglas, et al.
Bipolar Disorders|July 31, 2024
Cognitive predictors of response to interpersonal and social rhythm therapy in mood disordersSamantha J Groves, Katie M Douglas, Marie T Crowe, et al.
Plos One|August 25, 2022
AcceSS and Equity in Transplantation (ASSET) New Zealand: Protocol for population-wide data linkage platform to investigate equity in access to kidney failure health services in New ZealandRachel B Cutting, Angela C Webster, Nicholas B Cross, et al.
Internal Medicine Journal|September 17, 2022
Symptom persistence and recovery among COVID-19 survivors during a limited outbreak in Canterbury, New Zealand: a prospective cohort studyJeanette Cheung, Kim Nordmeier, Sarah Kelland, et al.
Pageof 9